The effect of epoprostenol on platelet activation and consumption during experimental extracorporeal perfusion

Artificial Organs

Volumn 23, Issue 11, 1999, Pages 984-987

  Skogby, Maria ^a   Adrian, Katrin ^a   Friberg, LarsGöran ^a   Mellgren, Karin ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Epoprostenol; Extracorporeal life support; Platelet glycoproteins; Platelets

Indexed keywords

CHEMICAL ACTIVATION; GLYCOPROTEINS;

BLEEDINGS; EPOPROSTENOL; EXTRACORPOREAL LIFE SUPPORTS; HAEMORRAGE; HUMAN BLOODS; IN-VITRO; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN; PLATELET MEMBRANES; THROMBOCYTOPENIA;

PLATELETS;

PROSTACYCLIN;

CONFERENCE PAPER; DRUG EFFECT; EXTRACORPOREAL OXYGENATION; HEMOSTASIS; HEPARINIZATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

EID: 0032727715     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1999.06452.x     Document Type: Conference Paper

References (15)

1. Zwischenberger J, Nguyen T, Upp R. Complications of neonatal extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 1994;107:838-48.
2. Toomasian J, Snedecor S, Cornell R. National experience with extracorporeal membrane oxygenation for newborn respiratory failure. ASAIO Trans 1988;34:140-7.
3. Mellgren K, Friberg LG, Hedner T, Mellgren G, Wadenvik H. Blood platelet activation and membrane glycoprotein changes durins extracorporeal life support (ECLS). In vitro studies. Int J Artif Organs 1995;18:315-21.
4. Mellgren K, Skogby M, Järnås A, Friberg LG, Wadenvik H, Mellgren G. Platelet activation and degradation in an experimental extracorporeal system. A comparison between a silicon membrane and a hollow-fibre oxygenator. Perfusion 1996;11:383-8.
5. Vroman L, Adams A, Fischer G, Munoz P. Interaction of high molecular weight kinogen, factor XII and fibrinogen in plasma interfaces. Blood 1980;55:156-9.
6. Sheppeck RA, Bentz M, Dickson C, Hribar S, White J, Janosky J, Berceli SA, Borovetz HS, Jonson PC. Examination of the roles of glycoprotein Ib and glycoprotein IIb/IIIa in platelet deposition on an artificial surface using clinical antiplatelet agents and monoclonal antibody blockade. Blood 1991;78(3):673-80.
7. Hogman M, Frostell C, Amberg H, Sandhagen B, Hedenstierna G. Prolonged bleeding time during nitric oxide inhalation in the rabbit. Acta Physiol Scand 1994;151:125-9.
8. Radomski M, Palmer R, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-8.
9. Bernabei A, Gikakis N, Kowalska M, Niewiarowski S, Edmunds L. Iloprost and echistatin protect platelets during simulated extracorporeal circulation. Ann Thorac Surg 1995;59:149-53.
10. Aren C, Feddersen K, Radegran K. Effects of prostacyclin infusion on platelet activation and postoperative blood loss in coronary bypass. Ann Thorac Surg 1983;1(36):49-54.
11. Fish K, Sarnquist F, Stennis Cv, Mitchell R, Hilberman M, Jamieson S. A prospective randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovas Surg 1986;91:436-42.
12. Grant S, Goa K. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;6(43)889-924.
13. Darious H, Veit K, Binz C, Fisch A, Meyer J. Diminished inhibition of adhesion molecule expression in prostacyclin receptor desentized human platelets. Mediators in the cardiovascular system. Region Ischem 1995;45:77-83.
14. Akkerman J, Willigen Gv. Platelet activation via trimeric GTP-binding proteins. Haemostasis 1996;4(26):199-209.
15. Korn R, Fischer C, Stenach N, Jeevanandam V, Addonizio V. Iloprost reduces procoagulant activity in the extracorporeal circuit. J Surg Res 1993;55:433-40.